Versatile RNA Interference Nanoplatform for Systemic Delivery of RNAs

Overview

Journal ACS Nano

Publisher American Chemical Society

Specialty Biotechnology

Date 2014 May 1

PMID 24779637

Citations 41

Authors

Ki Young Choi

Oscar F Silvestre

Xinglu Huang

Kyung Hyun Min

Gregory P Howard

Naoki Hida

Albert J Jin

Nicole Carvajal

Sang Wook Lee

Jong-In Hong

Xiaoyuan Chen

Affiliations

Soon will be listed here.

Abstract

Development of nontoxic, tumor-targetable, and potent in vivo RNA delivery systems remains an arduous challenge for clinical application of RNAi therapeutics. Herein, we report a versatile RNAi nanoplatform based on tumor-targeted and pH-responsive nanoformulas (NFs). The NF was engineered by combination of an artificial RNA receptor, Zn(II)-DPA, with a tumor-targetable and drug-loadable hyaluronic acid nanoparticle, which was further modified with a calcium phosphate (CaP) coating by in situ mineralization. The NF can encapsulate small-molecule drugs within its hydrophobic inner core and strongly secure various RNA molecules (siRNAs, miRNAs, and oligonucleotides) by utilizing Zn(II)-DPA and a robust CaP coating. We substantiated the versatility of the RNAi nanoplatform by demonstrating effective delivery of siRNA and miRNA for gene silencing or miRNA replacement into different human types of cancer cells in vitro and into tumor-bearing mice in vivo by intravenous administration. The therapeutic potential of NFs coloaded with an anticancer drug doxorubicin (Dox) and multidrug resistance 1 gene target siRNA (siMDR) was also demonstrated in this study. NFs loaded with Dox and siMDR could successfully sensitize drug-resistant OVCAR8/ADR cells to Dox and suppress OVCAR8/ADR tumor cell proliferation in vitro and tumor growth in vivo. This gene/drug delivery system appears to be a highly effective nonviral method to deliver chemo- and RNAi therapeutics into host cells.

Citing Articles

Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.

Umar A, Limpikirati P, Rivai B, Ardiansah I, Sriwidodo S, Luckanagul J Heliyon. 2025; 11(1):e41246.

PMID: 39811313 PMC: 11729671. DOI: 10.1016/j.heliyon.2024.e41246.

Endosomal escape: A bottleneck for LNP-mediated therapeutics.

Chatterjee S, Kon E, Sharma P, Peer D Proc Natl Acad Sci U S A. 2024; 121(11):e2307800120.

PMID: 38437552 PMC: 10945858. DOI: 10.1073/pnas.2307800120.

Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery.

Qiu C, Xia F, Zhang J, Shi Q, Meng Y, Wang C Research (Wash D C). 2023; 6:0148.

PMID: 37250954 PMC: 10208951. DOI: 10.34133/research.0148.

Advances and Challenges of Stimuli-Responsive Nucleic Acids Delivery System in Gene Therapy.

Lin M, Qi X Pharmaceutics. 2023; 15(5).

PMID: 37242692 PMC: 10220631. DOI: 10.3390/pharmaceutics15051450.

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.

Hamdy N, Eskander G, Basalious E Int J Nanomedicine. 2022; 17:6131-6155.

PMID: 36514378 PMC: 9741821. DOI: 10.2147/IJN.S386037.

References

Toole B, Slomiany M . Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol. 2008; 18(4):244-50. PMC: 2517221. DOI: 10.1016/j.semcancer.2008.03.009. View

Stern R, Jedrzejas M . Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006; 106(3):818-39. PMC: 2547145. DOI: 10.1021/cr050247k. View

Lee J, Hong J, Bonner D, Poon Z, Hammond P . Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater. 2012; 11(4):316-22. PMC: 3965374. DOI: 10.1038/nmat3253. View

Tseng Y, Mozumdar S, Huang L . Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 2009; 61(9):721-31. PMC: 3172140. DOI: 10.1016/j.addr.2009.03.003. View

Akinc A, Zumbuehl A, Goldberg M, Leshchiner E, Busini V, Hossain N . A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26(5):561-9. PMC: 3014085. DOI: 10.1038/nbt1402. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

Choi K, Saravanakumar G, Park J, Park K . Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces. 2011; 99:82-94. PMC: 3306773. DOI: 10.1016/j.colsurfb.2011.10.029. View

Rim H, Min K, Lee H, Jeong S, Lee S . pH-Tunable calcium phosphate covered mesoporous silica nanocontainers for intracellular controlled release of guest drugs. Angew Chem Int Ed Engl. 2011; 50(38):8853-7. DOI: 10.1002/anie.201101536. View

De Fougerolles A, Vornlocher H, Maraganore J, Lieberman J . Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007; 6(6):443-53. PMC: 7098199. DOI: 10.1038/nrd2310. View

10.

Choi K, Chung H, Min K, Yoon H, Kim K, Park J . Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2009; 31(1):106-14. DOI: 10.1016/j.biomaterials.2009.09.030. View

11.

Endoh T, Ohtsuki T . Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev. 2009; 61(9):704-9. DOI: 10.1016/j.addr.2009.04.005. View

12.

Daka A, Peer D . RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev. 2012; 64(13):1508-21. DOI: 10.1016/j.addr.2012.08.014. View

13.

Whitehead K, Langer R, Anderson D . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. PMC: 7097568. DOI: 10.1038/nrd2742. View

14.

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494-8. DOI: 10.1038/35078107. View

15.

Toole B . Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4(7):528-39. DOI: 10.1038/nrc1391. View

16.

Stern R . Hyaluronidases in cancer biology. Semin Cancer Biol. 2008; 18(4):275-80. DOI: 10.1016/j.semcancer.2008.03.017. View

17.

Rhee H, Choi S, Yoo S, Jang Y, Park H, Pinto R . A bifunctional molecule as an artificial flavin mononucleotide cyclase and a chemosensor for selective fluorescent detection of flavins. J Am Chem Soc. 2009; 131(29):10107-12. DOI: 10.1021/ja9018012. View

18.

Mok H, Lee S, Park J, Park T . Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010; 9(3):272-8. DOI: 10.1038/nmat2626. View

19.

Rhee H, Lee S, Shin I, Choi S, Park H, Han K . Detection of kinase activity using versatile fluorescence quencher probes. Angew Chem Int Ed Engl. 2010; 49(29):4919-23. DOI: 10.1002/anie.201000879. View

20.

Kong Y, Ferland-McCollough D, Jackson T, Bushell M . microRNAs in cancer management. Lancet Oncol. 2012; 13(6):e249-58. DOI: 10.1016/S1470-2045(12)70073-6. View